article thumbnail

Physician venture investor talks telehealth, digital therapeutics, Medicaid tech

Healthcare It News

Norden is particularly passionate about funding companies focused on the Medicaid population – a traditionally tricky and often ignored area. Companies like Pear Therapeutics, Limbix, Applied VR and Click Therapeutics are treating people with clinically validated and FDA-approved (or pending) digital interventions.

Medicaid 362
article thumbnail

Hims? Hers? It’s Novo Nordisk’s Semaglutide Market Now

Bill of Health

An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage. An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage.

FDA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HIMSSCast: Predicting what's next for health IT, mobile tech and health system finances

Healthcare It News

FDA and evolving regulations for digital therapeutics, software as a medical device. Up to 18 million people could lose Medicaid coverage after COVID-19 PHE. Automation, and how it can help clinician burnout and back-office processes. Cybersecurity and the patient safety risks of ransomware.

COVID-19 344
article thumbnail

7 Behavioral Health Technology Trends to Watch in 2025

HIT Consultant

The FDA is approving digital therapeutics tools (i.e., The Centers for Medicare & Medicaid Services (CMS) added codes for Digital Mental Health Treatment in its 2025 Medicare Physician Fee Schedules. In the meantime, patients and providers will have difficulty discerning what works and what doesn’t. Digital Therapeutics.

FDA 111
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. FDA validation of surrogate endpoints in oncology: 2005-2022. Subst Abuse.

FDA 241
article thumbnail

Insurance Coverage for Psychedelic Therapy

Bill of Health

By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. This is typical—without a seal of approval from FDA, insurers are reluctant to pay for off-label treatments. for depression).

FDA 203
article thumbnail

Medicare to broaden coverage of Alzheimer’s drugs after full FDA approval, but with some restrictions

Fierce Healthcare

The Centers for Medicare and Medicaid Services outlined plans Thursday to broadly cover a new class of Alzheimer’s drugs once the medications get full approval from the Food and Drug Administration | CMS outlined plans Thursday to broadly cover a new class of Alzheimer’s drugs once the medications get full approval from the Food and Drug Administration. (..)

Medicare 145